Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 10/20 | 0.62 |
| ▸ | SLC6A15 | Q9H2J7 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989409 | 0.87 | HRH1 (0.61) | HRH1SLC6A15MEN1NPC1CACNA1F | |
| SCHEMBL6988373 | 0.87 | HRH1 (0.61) | HRH1SLC6A15MEN1NPC1CACNA1F | |
| SCHEMBL6991396 | 0.86 | HRH1 (0.60) | HRH1SLC6A15MEN1NPC1CACNA1F | |
| SCHEMBL7092907 | 0.82 | SETD7 (0.56) | HRH1MEN1ABCB11LMNATP53 | |
| SCHEMBL9850494 | 0.81 | HRH1 (0.76) | HRH1SLC6A15MEN1NPC1CACNA1F | |
| SCHEMBL18102086 | 0.79 | HRH1 (0.67) | HRH1SLC6A15MEN1NPC1CACNA1F | |
| SCHEMBL7136762 | 0.79 | HRH1 (0.64) | HRH1SLC6A15MEN1NPC1CACNA1F | |
| SCHEMBL6988256 | 0.78 | HRH1 (0.57) | HRH1SLC6A15MEN1NPC1CACNA1F | |
| SCHEMBL7095067 | 0.77 | HRH1 (0.41) | HRH1MEN1LMNACHRM2ABCB1 | |
| SCHEMBL9075423 | 0.77 | HRH1 (1.00) | HRH1SLC6A15MEN1NPC1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888352-B1 | FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-28 | — | — | EP | disclosed |
| US-20030087895-A1 | Fused imidazole derivatives as multidrug resistance modulators | JANSSENS FRANS EDUARD (BE) | 2003-05-08 | — | — | US | disclosed |
| US-6544979-B1 | Having multidrug resistance modulating properties | JANSSEN PHARMACEUTICALS, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-1011726-B1 | FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-26 | — | — | EP | disclosed |
| US-6476018-B1 | Fused imidazole derivatives as multidrug resistance modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-11-05 | — | — | US | disclosed |
| US-6218381-B1 | FOR DECREASING, ELIMINATING OR REVERSING A DEVELOPING OR EXISTING RESISTANCE TO CHEMOTHERAPEUTIC DRUG THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-17 | — | — | US | disclosed |
| EP-1011726-A2 | FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999013871-A2 | FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087895-A1 | Fused imidazole derivatives as multidrug resistance modulators | ABCC1, CBR1, ABCB11 | HRH1 73/4885SLC6A15 231/4885MEN1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.